Summary of project PR000675
This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR000675. The data can be accessed directly via it's Project DOI: 10.21228/M8DX19 This work is supported by NIH grant, U2C- DK119886.
See: https://www.metabolomicsworkbench.org/about/howtocite.php
| Project ID: | PR000675 |
| Project DOI: | doi: 10.21228/M8DX19 |
| Project Title: | Mayo Pilot and Feasibility: The Enterohepatic Metabolome in Primary Sclerosing Cholangitis |
| Project Summary: | Emerging in vitro and in vivo data, including work from our laboratory and clinical research group, suggest fundamental pathophysiologic mechanisms in primary sclerosing cholangitis (PSC) that are centered on the enterohepatic circulation of gut-derived molecules. Therefore, in this proposal, we will test the central hypothesis that increased pathologic enterohepatic circulation of enteric metabolites which trigger specific pro-fibroinflammatory hepatobiliary responses are centrally involved in the etiopathogenesis of primary sclerosing cholangitis (PSC). While these processes have been hypothesized to play a significant role in the initiation, progression, and adverse clinical sequelae of PSC, they have not been directly tested to date. In our proposal, we will experimentally address the nature and extent of the metabolomic profiles of portal and peripheral blood as well as bile in patients with PSC. We will perform qualitative and quantitative ultra-performance liquid chromatography/mass spectroscopy-based metabolomic analyses to determine metabolic changes in portal and peripheral plasma and bile. Through subsequent pathway analyses we intend to identify metabolic enzymes and known biochemical pathways that may be altered in PSC. We anticipate that patients with PSC will have distinct alterations in the portal venous and bile metabolomic profiles and associated signaling pathways compared to normal and disease controls; and these alterations may be amenable to pharmacologic manipulation and future therapies. |
| Institute: | Mayo Clinic |
| Last Name: | O'Hara |
| First Name: | Steven |
| Address: | 200 First St. SW, Rochester, Minnesota, 55905, USA |
| Email: | ohara.steven@mayo.edu |
| Phone: | 507-284-1006 |
Summary of all studies in project PR000675
| Study ID | Study Title | Species | Institute | Analysis(* : Contains Untargted data) | Release Date | Version | Samples | Download(* : Contains raw data) |
|---|---|---|---|---|---|---|---|---|
| ST000995 | Amino Acid Concentrations of Primary Sclerosing Cholangitis (part I) | Homo sapiens | Mayo Clinic | MS | 2019-07-17 | 1 | 33 | Not available |
| ST000996 | Non-Esterified Fatty Acids of Primary Sclerosing Cholangitis (part II) | Homo sapiens | Mayo Clinic | MS | 2019-07-17 | 1 | 33 | Not available |
| ST000997 | Acyl Carnitines Concentrations of Primary Sclerosing Cholangitis (part III) | Homo sapiens | Mayo Clinic | MS | 2019-07-17 | 1 | 33 | Not available |
| ST000998 | Bile Acid of Primary Sclerosing Cholangitis (part IV) | Homo sapiens | Mayo Clinic | MS | 2019-07-17 | 1 | 33 | Not available |
